Michał Jarząb

Head of Department

Maria Sklodowska-Curie National Research Institute of Oncology

Poland

Research Interests

Explore related searches

Professors in Poland Professors in Cancer Biology Cancer Biology professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michał Jarząb is the Head of the Department at the Maria Sklodowska-Curie National Research Institute of Oncology in Poland. His research focuses on the efficacy of radiotherapy and cyclin-dependent kinase 4/6 inhibitors in the treatment of breast cancer, particularly in patients with metastatic conditions. Recent publications include studies on the clinical outcomes of metaplastic breast carcinoma and the use of liquid biopsy for advanced breast cancer management.

Articles (17)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Aleksandra Krzywon

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Tomasz Rutkowski

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Marcin Kubeczko

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Rafal Tarnawski

Head of Department

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michał Jarząb

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi-centre experience

Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors

Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis (vol 187, 109839, 2023)

Cyclin-dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in the Management of Brain Metastases in HR-positive/HER2-negative Breast Cancer Patients

Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients

Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data

MiRNA in archival serum samples derived from breast cancer patients treated with neoadjuvant chemotherapy vs freshly collected samples: Pilot study

Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study

Sternotomy and extracorporal circulation for fulminant Budd-Chiari syndrome due to leiomyosarcoma of the inferior vena cava

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer

Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients

Magnetic resonance imaging in patients with cardiac implantable electronic devices in a cardio-oncology center

Moderate adverse events and regional differ- ences in CDK4/6 inhibitor treatment combined with palliative radiotherapy

Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial

Collaborators (4)

Aleksandra Krzywon

Tomasz Rutkowski

Marcin Kubeczko

Rafal Tarnawski

Make your next move.